Drugmaker Patent Accords Delaying Generics Up 63%, FTC Says
Drugmaker Patent Accords Delaying Generics Up 63%, FTC Says
Drug company deals to delay the introduction of generic drugs rose 63 percent last year, Chairman Jon Leibowitz of the Federal Trade Commission said, calling the arrangements collusive and costly to consumers.